The histone deacetylase inhibitor tucidinostat, when used in combination with exemestane for treating patients with advanced, HR-positive, HER2-negative breast cancer, prolongs progression-free survival and substantially increases overall response and clinical benefit, while having a manageable safety profile, as shown in the results of the phase III ACE trial.
Treatment with nebivolol yields more favourable changes in 24-hour, intradialytic and daytime systolic and diastolic blood pressure variability in patients with intradialytic hypertension, a study has found.
Intraoperative methylprednisolone does not appear to significantly prevent the incidence of death, cardiac arrest and other injuries in neonates undergoing cardiac surgery with cardiopulmonary bypass, according to a recent study.
Treatment with low-to-standard dose dual combination therapy of blood pressure (BP)-lowering drugs is more effective than standard-dose monotherapy and does not increase withdrawals due to adverse events, a recent study has shown.
Treatment with metformin does not appear to provide an additional benefit of reducing the incidence of cancers, excluding those of the prostate and pancreas, in patients with diabetes, as reported in a study.
Concomitant use of conventional synthetic disease-modifying antirheumatic drug (csDMARD) results in a significantly lower risk for discontinuation of biologic (b)DMARD because of adverse events (AEs) among patients with rheumatoid arthritis (RA), according to a recent study.
Anti-tumour necrosis factor α (anti-TNFα) agents are better than other conventional therapies at preventing the clinical, endoscopic and histological postoperative recurrence of Crohn’s disease, reports a recent meta-analysis.
On 8 August, the first town hall held by the Ministry of Health (MOH) with members of the pharmacy profession took place in Putrajaya. Over 500 pharmacists from across the country and from different areas of practice—community and hospital, public and private, academy and industry—converged to fill the auditorium for the chance to engage in direct dialogue with MOH.
Adding pertuzumab to trastuzumab plus an aromatase inhibitor (AI) improves progression-free survival (PFS) in patients with HER2-positive metastatic or locally advanced breast cancer, the phase II PERTAIN study has shown.
Use of alpha blockers in the treatment of hypertension in women is associated with an increased risk of hypotension and related events as compared with other blood pressure-lowering drugs, as reported in a recent study.